Lupus Drug Trials Are Focusing On Clinical Response, Not Organ Endpoints
Trials of the latest drug candidates for systemic lupus erythematosus are focusing on clinical response claims rather than taking the organ-specific approach used for prior investigational lupus agents
You may also be interested in...
Pharmacometric analysis can be used to refine the design of further studies following failed clinical trials, according to an analysis by reviewers in FDA's Office of Clinical Pharmacology & Biopharmaceutics
FDA's draft guidance on lupus drug development allows for the use of clinical trials on specific organs to support a broader lupus claim
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011